en · de · es · fr · pt
faq-desk.peptides6155.com › Guide › Background And Pharmacological Mechanism — Deep Dive

Background And Pharmacological Mechanism — Deep Dive

By Editorial Desk · published 2025-11-24 · last reviewed 2026-01-06 · Guide

The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-01-06. Anything still debated is marked as such rather than presented as settled.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Related pages on this site

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Background from the literature

Molecular formaldehyde. A colorless gas with a characteristic sweetish-pungent irritating odor. It is stable at about 150 °C, but polymerizes when condensed to a liquid. 1,3,5-Trioxane, with the formula (CH2O)3. It is a white solid that dissolves without degrading in organic solvents. It is a trimer of molecular formaldehyde. Paraformaldehyde, with the formula HO(CH2O)nH. It is a white solid that is insoluble in most solvents. It slowly releases monomeric formaldehyde at room temperature. Methanediol, with the formula CH2(OH)2. This compound also exists in equilibrium with various oligomers (short polymers), depending on the concentration and temperature. A saturated water solution, of about 40% formaldehyde by volume or 37% by mass, is called "100% formalin". A small amount of stabilizer, such as methanol, is usually added to suppress oxidation and polymerization. A typical commercial-grade formalin may contain 10–12% methanol as well as metallic impurities. "Formaldehyde" was first used as a generic trademark in 1893 following a previous trade name, "formalin".

Jason Wilson of The Guardian said that Schmitt was "attempting to articulate white nationalist politics in a way that is not so explicit that people who aren't clued into this sort of stuff will notice." In April 2025, when asked about Trump's defunding of Title X grants to Missouri healthcare providers, Schmitt said he would be "happy to look at it more closely" and questioned the severity of the defunding of federal programs. Also in April, Schmitt filed a bill to make Easter Monday a federal holiday.

Candelariella deppeanae is a species of lichen in the family Candelariaceae. Found in southwestern North America, it was formally described as a new species in 2007 by the Swedish lichenologist Martin Westberg. The type specimen was collected in the Chiricahua Mountains (Chiricahua National Monument, Arizona) at an elevation of 1,750 m (5,740 ft). Here, in an oak forest, it was found growing on a decorticated (barkless) part of alligator juniper (Juniperus deppeana). Most collections of the lichen are from the wood or trunks of this juniper plant; the species epithet deppeanae alludes to this close relationship. The lichen has a greenish-yellow to yellow, granular to areolate thallus. It has also been collected in Texas, and from Chihuahua, Baja California Norte and Baja California Sur. The lichen grows mainly on wood and decorticated trunks, but has also been less frequently recorded growing on bark. Secondary chemicals that have been detected in Candelariella deppeanae (using high-performance liquid chromatography) include calycin, pulvic acid lactone, vulpinic acid, and pulvinic acid.

cytology The study of the morphology, processes, and life history of living cells, particularly by means of light and electron microscopy. The term is also sometimes used as a synonym for the broader field of cell biology.

== Translational readthrough == Stop codon suppression or translational readthrough occurs when in translation a stop codon is interpreted as a sense codon, that is, when a (standard) amino acid is 'encoded' by the stop codon. Mutated tRNAs can be the cause of readthrough, but also certain nucleotide motifs close to the stop codon. Translational readthrough is very common in viruses and bacteria, and has also been found as a gene regulatory principle in humans, yeasts, bacteria and drosophila. This kind of endogenous translational readthrough constitutes a variation of the genetic code, because a stop codon codes for an amino acid. In the case of human malate dehydrogenase, the stop codon is read through with a frequency of about 4%. The amino acid inserted at the stop codon depends on the identity of the stop codon itself: Gln, Tyr, and Lys have been found for the UAA and UAG codons, while Cys, Trp, and Arg for the UGA codon have been identified by mass spectrometry. Extent of readthrough in mammals have widely variable extents, and can broadly diversify the proteome and affect cancer progression.

Sources: en.wikipedia.org

Further detail

2 AgNO3 → 2 Ag + O2 + 2 NO2 Most metal nitrates thermally decompose to the respective oxides. This may be the case for silver nitrate. Unlike most metal oxides, however, silver oxide readily degrades to the elemental silver.

== Synthesis == Pancreatic polypeptide is synthesised and secreted by PP cells (also known as gamma cells or F cells) of the pancreatic islets of the pancreas. These are found predominantly in the head of the pancreas.

=== Guatemala === The Mexican Army crackdown has driven some cartels to seek a safer location for their operations across the border in Guatemala, attracted by corruption, weak policing, and its position on the overland smuggling route. The smugglers pick up drugs from small planes that land at private airstrips hidden in the Guatemalan jungle. The cargo is then moved up through Mexico to the U.S. border. Guatemala has also arrested dozens of drug suspects and torched huge cannabis and poppy fields. The U.S. government sent speedboats and night-vision goggles under a regional drug aid package. Los Zetas have gained ground in Guatemala after they killed several high-profile members and the supreme leader of Los Leones, an organized crime group from Guatemala. In February 2009, Los Zetas threatened to kill the president of Guatemala, Álvaro Colom. On March 1, 2010, Guatemala's chief of national police and the country's top anti-drugs official were arrested over alleged links to drug trafficking. A report from the Brookings Institution warns that, without proactive, timely efforts, the violence will spread throughout the Central American region. In August 2025, Guatemala granted temporary humanitarian status to 161 Mexicans fleeing cartel violence in Chiapas.

=== Cardiac === ANP inhibits cardiac hypertrophy in heart failure as well as fibrosis. Fibrosis is inhibited by preventing fibroblasts from entering heart tissue and replicating, as well as decreasing inflammation. ANP prevents hypertrophy by inhibiting calcium influx that is caused by norepinephrine. Re-expression of NPRA rescues the phenotype.

Sources: en.wikipedia.org

Background from the literature

== History == Diazepam was the second benzodiazepine invented by Leo Sternbach of Hoffmann-La Roche at the company's Nutley, New Jersey, facility following chlordiazepoxide (Librium), which was approved for use in 1960. Released in 1963 as an improved version of Librium, diazepam became incredibly popular, helping Roche to become a pharmaceutical industry giant. It is 2.5 times more potent than its predecessor, which it quickly surpassed in terms of sales. After this initial success, other pharmaceutical companies began to introduce other benzodiazepine derivatives. Medical professionals adopted the benzodiazepines as an improvement over barbiturates, which have a comparatively narrow therapeutic index, and are far more sedative at therapeutic doses. The benzodiazepines are also far less dangerous; death rarely results from diazepam overdose, except in cases where it is consumed with large amounts of other depressants (such as alcohol or opioids). Benzodiazepine drugs such as diazepam initially had widespread public support, but with time the view changed to one of growing criticism and calls for restrictions on their prescription. Marketed by Roche using an advertising campaign conceived by the William Douglas McAdams Agency under the leadership of Arthur Sackler, diazepam was the top-selling pharmaceutical in the United States from 1969 to 1982, with peak annual sales in 1978 of 2.3 billion tablets. Diazepam, along with oxazepam, nitrazepam and temazepam, represents 82% of the benzodiazepine market in Australia.

== Mechanism of action == Ondelopran appears to be an antagonist at opioid receptors, which means it blocks the action of other opioids (including endogenous opioids like endorphins) by preventing them from binding to the receptor. It antagonizes the three primary opioid receptors with potency of 0.4 (mu), 0.6 (kappa), and 1.9 nM (delta).

where Bn is the binding energy of the captured electron. Because the binding energy of the electron is much less than the mass of the electron, nuclei that can undergo β+ decay can always also undergo electron capture, but the reverse is not true.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Network